Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation
- 8 January 2014
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 84 (1), 37-45
- https://doi.org/10.1002/ccd.25378
Abstract
Objectives This study sought to investigate the postdeployment expansion and malapposition characteristics of the bioresorbable vascular scaffold (BVS) in real-world practice. Background The material construct of the BVS precludes overexpansion, with consequent potential for scaffold underexpansion and malapposition. In metallic stents, these features are associated with an increased risk of adverse events, including stent thrombosis. The postdeployment characteristics of the BVS are yet to be described outside clinical trials, where implantation occurred in straightforward lesion subsets. Methods Data from 25 patients undergoing BVS implantation were analyzed. Optical coherence tomography (OCT) was performed both before and after intervention to assess plaque composition, scaffold expansion and strut apposition. Manufacturer's compliance charts were used to predict expected minimal scaffold diameter and area. Results OCT pullback (522.2 mm) was analyzed. Overall, BVS achieved 82.5 ± 8.7 and 79.8 ± 12.3% of predicted minimal stent diameter and cross-sectional area (SCA), respectively, with expansion reduced in middle third of the scaffold (central SCA 76.7 ± 10.9% vs. noncentral SCA 81.5 ± 12.7%, P < 0.0001). Improved measures of SCA were observed with 1:1 balloon:vessel predilatation (1:1 PreD 82.8 ± 9.5% vs. No 1:1 PredD 78.6 ± 13.0%, P < 0.0001). Seven thousand six hundred scaffold struts were identified, of which 470 (6.18%) were malapposed. In fibrocalcific (FCa) plaques, malapposition was observed more frequently (FCa 44.4% vs. Other plaques 7.5%, P < 0.001) and at a greater distance from the vessel wall (FCa 0.17 ± 0.10 mm vs. Other plaques 0.14 ± 0.08 mm, P = 0.002). Conclusions In this study, BVS expansion was significantly improved by 1:1 PreD, while increased rates of malapposition was associated with FCa plaques.Keywords
This publication has 28 references indexed in Scilit:
- Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantationEuropean Heart Journal, 2012
- Bioresorbable Polymeric Vascular ScaffoldsCirculation: Cardiovascular Interventions, 2011
- Bioresorbable ScaffoldCirculation, 2011
- Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trialThe International Journal of Cardiovascular Imaging, 2011
- Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery StenosisCirculation, 2010
- Coronary Stents: Looking ForwardJournal of the American College of Cardiology, 2010
- A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methodsThe Lancet, 2009
- Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound studyJournal of the American College of Cardiology, 2005
- Contribution of Stent Underexpansion to Recurrence After Sirolimus-Eluting Stent Implantation for In-Stent RestenosisCirculation, 2004
- Predictors and outcomes of stent thrombosis. An intravascular ultrasound registryEuropean Heart Journal, 2002